← Eichor
Study identifier: NCT04642027 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy

Condition: Prostate Cancer · Cancer Recurrence  ·  Sponsor: University Medical Center Groningen

PhasePhase 3
Planned participants538
Who can joinMale, 18 Years to 80 Years
Healthy volunteersNo

About this study

After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT). sEBRT can provide long-term disease control; with 5 year biochemical progression-free survival (bPFS) up to 60% and with most treatment failures in the first 2 years after sEBRT. The main goal of this project is to investigate whether the oncologic outcome in patients with post-prostatectomy recurrent PCa can be improved, by increasing the biological effective radiation dose using a hypofractionated schedule of 20 x 3 = 60 Gy. The study is designed as a prospective open phase III randomized multicenter trial. All patients with biochemical recurrence with a PSA \< 1.0 ng/ml after radical prostatectomy for prostate cancer without evidence of lymph nodes or distance metastases will be included. PSA progression after prostatectomy defined as two consecutive rises with the final PSA \> 0.1 ng/mL or three consecutive rises will be included. All eligible patients will be randomized to one of the following two treatment arms: Arm 1 = Conventional sEBRT to apply a total dose of 70 Gy in 35 daily fractions of 2 Gy during 7 weeks. Arm 2 = Hypofractionated sEBRT to apply a total dose of 60 Gy in 20 fractions of 3 Gy during 4 weeks. The primary endpoint will be the 5-year progression-free survival (PFS) after treatment.

This description comes directly from the study's public registry record.

Talk to the study team

F. Staal, MD  ·  0031655257985  ·  f.h.e.staal@umcg.nl

P. Veldhuijzen van Zanten  ·  0031503614659  ·  peryton@rt.umcg.nl

Always discuss trial participation with your own doctor first.

Locations (13)

RadiotherapiegroepArnhem, Gelderland, NetherlandsRecruiting
Radboud University Medical CenterNijmegen, Gelderland, NetherlandsRecruiting
Maastro ClinicMaastricht, Limburg, NetherlandsRecruiting
Catharina-HospitalEindhoven, North Brabant, NetherlandsRecruiting
Verbeeten InstituteTilburg, North Brabant, NetherlandsRecruiting
Amsterdam UMC (Location VUmc)Amsterdam, North Holland, NetherlandsNot Yet Recruiting
RadiotherapiegroepDeventer, Overijssel, NetherlandsRecruiting
Radiotherapy Institute FrieslandLeeuwarden, Provincie Friesland, NetherlandsRecruiting
Leiden University Medical CenterLeiden, South Holland, NetherlandsNot Yet Recruiting
Erasmus Medical CenterRotterdam, South Holland, NetherlandsNot Yet Recruiting
Haga HospitalThe Hague, South Holland, NetherlandsNot Yet Recruiting
Zuidwest Radiotherapeutisch Instituut (ZRTI)Flushing, NetherlandsRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04642027